" /> Vamotinib - CISMeF





Preferred Label : Vamotinib;

NCIt synonyms : Bcr-Abl Inhibitor PF-114; Bcr-Abl Kinase Inhibitor PF-114;

NCIt definition : An orally bioavailable, Bcr-Abl tyrosine kinase inhibitor, with potential antineoplastic activity. Designed to overcome resistance of tumor cells to second generation Bcr-Abl inhibitors, vamotinib targets and binds to the Bcr-Abl fusion oncoprotein, including those fusion proteins with the 'gatekeeper' resistance mutation T315I, an amino acid substitution at position 315 in Bcr-Abl from a threonine (T) to an isoleucine (I). This inhibits Bcr-Abl-mediated proliferation of, and enhances apoptosis in, Philadelphia chromosome-positive (Ph ) hematologic malignancies. The Bcr-Abl fusion protein is an aberrantly activated tyrosine kinase produced by leukemia cells that contain the Philadelphia chromosome.;

UNII : I8C3R768IZ;

CAS number : 1416241-23-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1416241-23-0 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : PF-114;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
16/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.